| __timestamp | BioCryst Pharmaceuticals, Inc. | Veracyte, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 7461000 | 40786000 |
| Thursday, January 1, 2015 | 13047000 | 47876000 |
| Friday, January 1, 2016 | 11253000 | 52035000 |
| Sunday, January 1, 2017 | 13933000 | 55348000 |
| Monday, January 1, 2018 | 29514000 | 65276000 |
| Tuesday, January 1, 2019 | 37121000 | 82720000 |
| Wednesday, January 1, 2020 | 67929000 | 89118000 |
| Friday, January 1, 2021 | 118818000 | 181193000 |
| Saturday, January 1, 2022 | 159371000 | 174078000 |
| Sunday, January 1, 2023 | 213894000 | 184232000 |
Unlocking the unknown
In the competitive landscape of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability and operational efficiency. Over the past decade, Veracyte, Inc. and BioCryst Pharmaceuticals, Inc. have shown distinct trends in their SG&A expenditures. From 2014 to 2023, Veracyte's SG&A costs increased by approximately 350%, peaking in 2023. In contrast, BioCryst's expenses surged by nearly 280% during the same period. Notably, Veracyte consistently maintained higher SG&A expenses, with a mean of $97 million compared to BioCryst's $67 million. This suggests Veracyte's aggressive investment in administrative functions, potentially reflecting a strategy focused on rapid growth and market expansion. Meanwhile, BioCryst's more conservative spending could indicate a focus on cost efficiency. Understanding these trends provides valuable insights into each company's strategic priorities and financial health.
Selling, General, and Administrative Costs: AbbVie Inc. vs Veracyte, Inc.
Merck & Co., Inc. and Veracyte, Inc.: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Viatris Inc. and BioCryst Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Walgreens Boots Alliance, Inc. and Veracyte, Inc.
Selling, General, and Administrative Costs: Exelixis, Inc. vs BioCryst Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Veracyte, Inc. and HUTCHMED (China) Limited
Operational Costs Compared: SG&A Analysis of Veracyte, Inc. and Travere Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of ACADIA Pharmaceuticals Inc. and BioCryst Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Arrowhead Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc.
ImmunityBio, Inc. vs BioCryst Pharmaceuticals, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Dynavax Technologies Corporation or BioCryst Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Travere Therapeutics, Inc. vs BioCryst Pharmaceuticals, Inc.